Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
MTD vs BRKR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
MTD vs BRKR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Devices |
| Market Cap | $26.85B | $6.66B |
| Revenue (TTM) | $4.09B | $3.46B |
| Net Income (TTM) | $875M | $-12M |
| Gross Margin | 57.8% | 45.3% |
| Operating Margin | 28.0% | 4.9% |
| Forward P/E | 28.4x | 20.7x |
| Total Debt | $2.34B | $2.04B |
| Cash & Equiv. | $67M | $299M |
MTD vs BRKR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mettler-Toledo Inte… (MTD) | 100 | 166.2 | +66.2% |
| Bruker Corporation (BRKR) | 100 | 101.0 | +1.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MTD vs BRKR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MTD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.31
- Rev growth 4.0%, EPS growth 3.7%, 3Y rev CAGR 0.9%
- 267.1% 10Y total return vs BRKR's 67.1%
BRKR is the clearest fit if your priority is value and dividends.
- Lower P/E (20.7x vs 28.4x)
- 0.3% yield; the other pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.0% revenue growth vs BRKR's 2.1% | |
| Value | Lower P/E (20.7x vs 28.4x) | |
| Quality / Margins | 21.4% margin vs BRKR's -0.3% | |
| Stability / Safety | Beta 1.31 vs BRKR's 1.59 | |
| Dividends | 0.3% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +21.8% vs BRKR's +7.8% | |
| Efficiency (ROA) | 24.5% ROA vs BRKR's -0.2%, ROIC 40.0% vs 4.4% |
MTD vs BRKR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MTD vs BRKR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MTD leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MTD and BRKR operate at a comparable scale, with $4.1B and $3.5B in trailing revenue. MTD is the more profitable business, keeping 21.4% of every revenue dollar as net income compared to BRKR's -0.3%. On growth, MTD holds the edge at +7.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.1B | $3.5B |
| EBITDAEarnings before interest/tax | $1.2B | $397M |
| Net IncomeAfter-tax profit | $875M | -$12M |
| Free Cash FlowCash after capex | $794M | $51M |
| Gross MarginGross profit ÷ Revenue | +57.8% | +45.3% |
| Operating MarginEBIT ÷ Revenue | +28.0% | +4.9% |
| Net MarginNet income ÷ Revenue | +21.4% | -0.3% |
| FCF MarginFCF ÷ Revenue | +19.4% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.2% | +2.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.5% | -79.2% |
Valuation Metrics
BRKR leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, BRKR's 18.4x EV/EBITDA is more attractive than MTD's 23.4x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $26.9B | $6.7B |
| Enterprise ValueMkt cap + debt − cash | $29.1B | $8.4B |
| Trailing P/EPrice ÷ TTM EPS | 31.33x | -291.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 28.41x | 20.68x |
| PEG RatioP/E ÷ EPS growth rate | 2.82x | — |
| EV / EBITDAEnterprise value multiple | 23.41x | 18.41x |
| Price / SalesMarket cap ÷ Revenue | 6.67x | 1.94x |
| Price / BookPrice ÷ Book value/share | — | 2.64x |
| Price / FCFMarket cap ÷ FCF | 31.64x | 153.73x |
Profitability & Efficiency
MTD leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
MTD delivers a 111.6% return on equity — every $100 of shareholder capital generates $112 in annual profit, vs $-0 for BRKR. On the Piotroski fundamental quality scale (0–9), MTD scores 6/9 vs BRKR's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +111.6% | -0.5% |
| ROA (TTM)Return on assets | +24.5% | -0.2% |
| ROICReturn on invested capital | +40.0% | +4.4% |
| ROCEReturn on capital employed | +48.8% | +5.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.81x |
| Net DebtTotal debt minus cash | $2.3B | $1.7B |
| Cash & Equiv.Liquid assets | $67M | $299M |
| Total DebtShort + long-term debt | $2.3B | $2.0B |
| Interest CoverageEBIT ÷ Interest expense | 13.02x | 1.14x |
Total Returns (Dividends Reinvested)
MTD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MTD five years ago would be worth $10,333 today (with dividends reinvested), compared to $6,447 for BRKR. Over the past 12 months, MTD leads with a +21.8% total return vs BRKR's +7.8%. The 3-year compound annual growth rate (CAGR) favors MTD at -1.8% vs BRKR's -16.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -6.4% | -9.0% |
| 1-Year ReturnPast 12 months | +21.8% | +7.8% |
| 3-Year ReturnCumulative with dividends | -5.2% | -42.5% |
| 5-Year ReturnCumulative with dividends | +3.3% | -35.5% |
| 10-Year ReturnCumulative with dividends | +267.1% | +67.1% |
| CAGR (3Y)Annualised 3-year return | -1.8% | -16.9% |
Risk & Volatility
MTD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MTD is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than BRKR's 1.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MTD currently trades 86.6% from its 52-week high vs BRKR's 77.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 1.59x |
| 52-Week HighHighest price in past year | $1525.17 | $56.22 |
| 52-Week LowLowest price in past year | $1059.24 | $28.53 |
| % of 52W HighCurrent price vs 52-week peak | +86.6% | +77.8% |
| RSI (14)Momentum oscillator 0–100 | 57.5 | 64.8 |
| Avg Volume (50D)Average daily shares traded | 148K | 1.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MTD as "Hold" and BRKR as "Buy". Consensus price targets imply 19.2% upside for BRKR (target: $52) vs 12.8% for MTD (target: $1491). BRKR is the only dividend payer here at 0.34% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $1490.83 | $52.13 |
| # AnalystsCovering analysts | 19 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | +0.3% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.0% | +0.2% |
MTD leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BRKR leads in 1 (Valuation Metrics).
MTD vs BRKR: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MTD or BRKR a better buy right now?
For growth investors, Mettler-Toledo International Inc.
(MTD) is the stronger pick with 4. 0% revenue growth year-over-year, versus 2. 1% for Bruker Corporation (BRKR). Mettler-Toledo International Inc. (MTD) offers the better valuation at 31. 3x trailing P/E (28. 4x forward), making it the more compelling value choice. Analysts rate Bruker Corporation (BRKR) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MTD or BRKR?
On forward P/E, Bruker Corporation is actually cheaper at 20.
7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — MTD or BRKR?
Over the past 5 years, Mettler-Toledo International Inc.
(MTD) delivered a total return of +3. 3%, compared to -35. 5% for Bruker Corporation (BRKR). Over 10 years, the gap is even starker: MTD returned +267. 1% versus BRKR's +67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MTD or BRKR?
By beta (market sensitivity over 5 years), Mettler-Toledo International Inc.
(MTD) is the lower-risk stock at 1. 31β versus Bruker Corporation's 1. 59β — meaning BRKR is approximately 21% more volatile than MTD relative to the S&P 500.
05Which is growing faster — MTD or BRKR?
By revenue growth (latest reported year), Mettler-Toledo International Inc.
(MTD) is pulling ahead at 4. 0% versus 2. 1% for Bruker Corporation (BRKR). On earnings-per-share growth, the picture is similar: Mettler-Toledo International Inc. grew EPS 3. 7% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MTD or BRKR?
Mettler-Toledo International Inc.
(MTD) is the more profitable company, earning 21. 6% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MTD leads at 27. 8% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — MTD leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MTD or BRKR more undervalued right now?
On forward earnings alone, Bruker Corporation (BRKR) trades at 20.
7x forward P/E versus 28. 4x for Mettler-Toledo International Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BRKR: 19. 2% to $52. 13.
08Which pays a better dividend — MTD or BRKR?
In this comparison, BRKR (0.
3% yield) pays a dividend. MTD does not pay a meaningful dividend and should not be held primarily for income.
09Is MTD or BRKR better for a retirement portfolio?
For long-horizon retirement investors, Mettler-Toledo International Inc.
(MTD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+267. 1% 10Y return). Bruker Corporation (BRKR) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTD: +267. 1%, BRKR: +67. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MTD and BRKR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.